Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

Simrén, Joel ; Leuzy, Antoine LU ; Karikari, Thomas K. ; Hye, Abdul ; Benedet, Andréa Lessa ; Lantero-Rodriguez, Juan ; Mattsson-Carlgren, Niklas LU orcid ; Schöll, Michael LU ; Mecocci, Patrizia and Vellas, Bruno , et al. (2021) In Alzheimer's and Dementia 17(7). p.1145-1156
Abstract

Introduction: This study investigated the diagnostic and disease-monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals. Methods: Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, and 103 AD dementia participants. Results: Phosphorylated-tau181 (P-tau181), neurofilament light, amyloid-β (Aβ42/40), Total-tau and Glial fibrillary acidic protein were altered in AD dementia but P-tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU (area under the curve [AUC] = 0.91). P-tau181 was increased in MCI converters compared to non-converters. Higher P-tau181 was associated with steeper cognitive... (More)

Introduction: This study investigated the diagnostic and disease-monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals. Methods: Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, and 103 AD dementia participants. Results: Phosphorylated-tau181 (P-tau181), neurofilament light, amyloid-β (Aβ42/40), Total-tau and Glial fibrillary acidic protein were altered in AD dementia but P-tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU (area under the curve [AUC] = 0.91). P-tau181 was increased in MCI converters compared to non-converters. Higher P-tau181 was associated with steeper cognitive decline and gray matter loss in temporal regions. Longitudinal change of P-tau181 was strongly associated with gray matter loss in the full sample and with Aβ measures in CU individuals. Discussion: P-tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss. These findings highlight the potential value of plasma P-tau181 as a non-invasive and cost-effective diagnostic and prognostic biomarker in AD.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, magnetic resonance imaging, phosphorylated tau, plasma biomarkers
in
Alzheimer's and Dementia
volume
17
issue
7
pages
12 pages
publisher
Wiley
external identifiers
  • pmid:33491853
  • scopus:85099864986
ISSN
1552-5260
DOI
10.1002/alz.12283
language
English
LU publication?
yes
id
78a09b9f-9139-4415-9ee0-80b4e92a083f
date added to LUP
2021-12-08 15:31:56
date last changed
2024-04-20 18:19:44
@article{78a09b9f-9139-4415-9ee0-80b4e92a083f,
  abstract     = {{<p>Introduction: This study investigated the diagnostic and disease-monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals. Methods: Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, and 103 AD dementia participants. Results: Phosphorylated-tau181 (P-tau181), neurofilament light, amyloid-β (Aβ42/40), Total-tau and Glial fibrillary acidic protein were altered in AD dementia but P-tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU (area under the curve [AUC] = 0.91). P-tau181 was increased in MCI converters compared to non-converters. Higher P-tau181 was associated with steeper cognitive decline and gray matter loss in temporal regions. Longitudinal change of P-tau181 was strongly associated with gray matter loss in the full sample and with Aβ measures in CU individuals. Discussion: P-tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss. These findings highlight the potential value of plasma P-tau181 as a non-invasive and cost-effective diagnostic and prognostic biomarker in AD.</p>}},
  author       = {{Simrén, Joel and Leuzy, Antoine and Karikari, Thomas K. and Hye, Abdul and Benedet, Andréa Lessa and Lantero-Rodriguez, Juan and Mattsson-Carlgren, Niklas and Schöll, Michael and Mecocci, Patrizia and Vellas, Bruno and Tsolaki, Magda and Kloszewska, Iwona and Soininen, Hilkka and Lovestone, Simon and Aarsland, Dag and Hansson, Oskar and Rosa-Neto, Pedro and Westman, Eric and Blennow, Kaj and Zetterberg, Henrik and Ashton, Nicholas J.}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; magnetic resonance imaging; phosphorylated tau; plasma biomarkers}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{1145--1156}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.1002/alz.12283}},
  doi          = {{10.1002/alz.12283}},
  volume       = {{17}},
  year         = {{2021}},
}